Solventum Corporation (NYSE:SOLV) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Solventum Corporation has received a consensus recommendation of "Hold" from twelve research firms, with price target estimates averaging $84.89.
• The company's latest quarterly earnings showed an EPS of $1.69, surpassing estimates and indicating a year-over-year revenue increase of 3.8%.
• Recent institutional trading activity includes new stakes acquired by several companies, indicating growing investor interest in Solventum's shares.

Shares of Solventum Corporation (NYSE:SOLV - Get Free Report) have received a consensus recommendation of "Hold" from the twelve research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $84.8889.

SOLV has been the topic of a number of research reports. Jefferies Financial Group initiated coverage on Solventum in a research report on Thursday, September 11th. They set a "hold" rating and a $80.00 price objective on the stock. Wells Fargo & Company boosted their price objective on Solventum from $79.00 to $82.00 and gave the company an "equal weight" rating in a research report on Monday, September 15th. Wall Street Zen lowered Solventum from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, September 9th. Argus raised Solventum from a "hold" rating to a "buy" rating and set a $90.00 price target on the stock in a research note on Tuesday, July 1st. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $94.00 price target (up previously from $87.00) on shares of Solventum in a research note on Friday, August 8th.

Solventum Stock Performance

SOLV opened at $70.53 on Friday. The stock has a market cap of $12.23 billion, a PE ratio of 32.65, a P/E/G ratio of 2.87 and a beta of 0.50. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. Solventum has a 1 year low of $60.70 and a 1 year high of $85.92. The stock's 50 day simple moving average is $72.75 and its 200-day simple moving average is $72.10.

Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.45 by $0.24. The business had revenue of $2.16 billion for the quarter, compared to analysts' expectations of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.Solventum's quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Sell-side analysts forecast that Solventum will post 6.58 EPS for the current year.

Institutional Trading of Solventum

Several institutional investors have recently bought and sold shares of SOLV. Rossby Financial LCC acquired a new stake in Solventum in the 1st quarter valued at $25,000. Strengthening Families & Communities LLC boosted its stake in Solventum by 376.8% in the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company's stock valued at $25,000 after buying an additional 260 shares in the last quarter. CYBER HORNET ETFs LLC acquired a new stake in Solventum in the 2nd quarter valued at $28,000. Barrett & Company Inc. boosted its stake in Solventum by 206.2% in the 2nd quarter. Barrett & Company Inc. now owns 398 shares of the company's stock valued at $30,000 after buying an additional 268 shares in the last quarter. Finally, IMG Wealth Management Inc. acquired a new stake in Solventum in the 2nd quarter valued at $31,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.